Eric Van Cutsem
Impact in
- Oncology top 0.01%
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Hepatology top 0.02%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 912
- Colorectal Cancer Treatments and Studies 638
- Cancer Treatment and Pharmacology 189
- Pancreatic and Hepatic Oncology Research 127
- Cancer Immunotherapy and Biomarkers 86
-
- Gastric Cancer Management and Outcomes 285
- Lung Cancer Treatments and Mutations 151
- Co-authors
- Josep Tabernero (251 shared papers)Salvatore Siena (63 shared papers)David Cunningham (71 shared papers)Marc Peeters (98 shared papers)Yves Humblet (45 shared papers)Philippe Rougier (32 shared papers)Bernard Nordlinger (41 shared papers)Atsushi Ohtsu (81 shared papers)
- Journals
- Journal of Clinical Oncology (451 papers)Annals of Oncology (249 papers)European Journal of Cancer (65 papers)ESMO Open (19 papers)Clinical Cancer Research (18 papers)
- Partner nations
- BelgiumUnited StatesSpain
In The Last Decade
Eric Van Cutsem
1.2k papers receiving 94.6k citations
Eric Van Cutsem's Hit Papers
Peers
Comparison fields: 5 of 178
- Oncology 55.8k
- Hepatology 10.4k
- Pulmonary and Respiratory Medicine 24.8k
- Gastroenterology 4.1k
- Cancer Research 9.7k
Countries citing papers authored by Eric Van Cutsem
This map shows the geographic impact of Eric Van Cutsem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Van Cutsem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Van Cutsem more than expected).
Fields of papers citing papers by Eric Van Cutsem
This network shows the impact of papers produced by Eric Van Cutsem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Van Cutsem. The network helps show where Eric Van Cutsem may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric Van Cutsem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.2k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Hit paper breakdown → | 2010 | 5344 |
| 2 | Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2004 | 3873 |
| 3 | Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer Hit paper breakdown → | 2009 | 2914 |
| 4 | Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 2406 |
| 5 | Everolimus for Advanced Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2011 | 2096 |
| 6 | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2012 | 2091 |
| 7 | Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2011 | 1814 |
| 8 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Hit paper breakdown → | 2014 | 1743 |
| 9 | Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer Hit paper breakdown → | 2019 | 1530 |
| 10 | Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2007 | 1520 |
| 11 | Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group Hit paper breakdown → | 2006 | 1485 |
| 12 | Gastric cancer Hit paper breakdown → | 2016 | 1460 |
| 13 | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer Hit paper breakdown → | 2018 | 1455 |
| 14 | Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status Hit paper breakdown → | 2011 | 1445 |
| 15 | Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Hit paper breakdown → | 2008 | 1403 |
| 16 | American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer Hit paper breakdown → | 2004 | 1094 |
| 17 | Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study Hit paper breakdown → | 2020 | 1012 |
| 18 | Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Hit paper breakdown → | 2012 | 992 |
| 19 | Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial Hit paper breakdown → | 2009 | 896 |
| 20 | Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 891 |
About Eric Van Cutsem
Eric Van Cutsem is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Cancer Research and Pathology and Forensic Medicine, having authored 1.2k papers that have together received 96.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (638 papers), Gastric Cancer Management and Outcomes (285 papers), Cancer Treatment and Pharmacology (189 papers), Lung Cancer Treatments and Mutations (151 papers), Pancreatic and Hepatic Oncology Research (127 papers), Genetic factors in colorectal cancer (116 papers), Cancer Genomics and Diagnostics (113 papers) and Cancer Immunotherapy and Biomarkers (86 papers). The work is most often cited by research in Oncology (55.8k citations), Hepatology (10.4k citations), Pulmonary and Respiratory Medicine (24.8k citations), Gastroenterology (4.1k citations) and Cancer Research (9.7k citations). Eric Van Cutsem has collaborated with scholars based in Belgium, United States and Spain. Frequent co-authors include Josep Tabernero, Salvatore Siena, David Cunningham, Marc Peeters, Yves Humblet, Philippe Rougier, Bernard Nordlinger, Atsushi Ohtsu, Chris Verslype and Yung‐Jue Bang. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, ESMO Open and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.